WO2024013271A1 - Colorimetric nucleic acid detection - Google Patents
Colorimetric nucleic acid detection Download PDFInfo
- Publication number
- WO2024013271A1 WO2024013271A1 PCT/EP2023/069406 EP2023069406W WO2024013271A1 WO 2024013271 A1 WO2024013271 A1 WO 2024013271A1 EP 2023069406 W EP2023069406 W EP 2023069406W WO 2024013271 A1 WO2024013271 A1 WO 2024013271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- nucleic acid
- leuco dye
- immobilized
- target nucleic
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 172
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 170
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 170
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 96
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 241000606153 Chlamydia trachomatis Species 0.000 claims abstract description 13
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims abstract description 13
- 241000224527 Trichomonas vaginalis Species 0.000 claims abstract description 13
- 229940038705 chlamydia trachomatis Drugs 0.000 claims abstract description 13
- 241000204051 Mycoplasma genitalium Species 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 239000000975 dye Substances 0.000 claims description 172
- 238000012360 testing method Methods 0.000 claims description 75
- 229920000642 polymer Polymers 0.000 claims description 47
- 230000003321 amplification Effects 0.000 claims description 36
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 239000012038 nucleophile Substances 0.000 claims description 30
- 229920000936 Agarose Polymers 0.000 claims description 27
- 239000002102 nanobead Substances 0.000 claims description 27
- 229920002301 cellulose acetate Polymers 0.000 claims description 25
- 229920005646 polycarboxylate Polymers 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 21
- -1 alkylammonium ion Chemical class 0.000 claims description 19
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 229920001661 Chitosan Polymers 0.000 claims description 16
- XFXPMWWXUTWYJX-UHFFFAOYSA-N isonitrile group Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 15
- 238000007397 LAMP assay Methods 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 14
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 claims description 14
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000003368 amide group Chemical group 0.000 claims description 12
- 125000001769 aryl amino group Chemical group 0.000 claims description 12
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- 125000005110 aryl thio group Chemical group 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 12
- 229940052223 basic fuchsin Drugs 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000002560 nitrile group Chemical group 0.000 claims description 12
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 229940107698 malachite green Drugs 0.000 claims description 10
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims description 10
- 229910002651 NO3 Inorganic materials 0.000 claims description 9
- 229910052783 alkali metal Inorganic materials 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000004927 clay Substances 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 150000001340 alkali metals Chemical class 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000000440 bentonite Substances 0.000 claims description 6
- 229910000278 bentonite Inorganic materials 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 150000004678 hydrides Chemical class 0.000 claims description 3
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 3
- 229910052987 metal hydride Inorganic materials 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000463 material Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 244000052769 pathogen Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulphite Substances [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000606161 Chlamydia Species 0.000 description 4
- 206010018612 Gonorrhoea Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000980 acid dye Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000012123 point-of-care testing Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012125 lateral flow test Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010072369 Pharyngeal exudate Diseases 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Definitions
- the application provides a method for detecting a target nucleic acid, the method comprising the steps of (a) amplifying a target nucleic acid providing an amplified nucleic acid; (b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and (c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid.
- the target nucleic acid is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- the present invention thus also relates to methods for determining whether a subject suffers from an infection caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis and associated diseases.
- STIs sexually transmitted infections
- WHO World Health Organization
- STIs chlamydia
- gonorrhoea 82 million
- syphilis 7.1 million
- trichomoniasis 156 million
- STIs Approximately 80% of the newly reported STI cases occur in developing countries, and disproportionately impact women. Since many infected individuals present as asymptomatic, STIs may go undetected for a long time leading to their further spread.
- STIs can lead to more severe consequences than the initial symptoms of the infection, including blindness, bone deformities, brain damage, cancer, heart disease, long-term reproductive complications, birth defects, and even death. Early and accurate diagnosis of infection is therefore essential to limit the spread and outcomes of the infection and provide patients with timely, appropriate, and effective treatment.
- Point-of-care tests have the potential to transform the prevention and control of STIs by enabling immediate diagnosis and early treatment of infections.
- the U.S. Food and Drug Administration has currently cleared three rapid tests for chlamydia and gonorrhoea and two for trichomonas.
- the Xpert® CT/NG assay produced by Cepheid® is anFDA cleared rapid test for Chlamydia and gonorrhoea, however it has not been waived by the Clinical Laboratory Improvement Amendments (CLIA).
- CLIA Clinical Laboratory Improvement Amendments
- This is a cartridge-based assay, relying on molecular Nucleic Acid Amplification Technology (NAATs), which is able to detect nucleic acids from pathogens.
- NAATs molecular Nucleic Acid Amplification Technology
- the Xpert cartridge combines microfluidic technology with real-time polymerase chain reaction (qPCR) allowing for amplification and detection in 90 minutes. Given the use qPCR, which involves thermocycling and a complex amplification process, the Xpert device is large, cumbersome and expensive, making it unsuitable for resource-limited settings.
- a second FDA approved and CLIA waived assay for chlamydia and gonorrhoea is the io device produced by binx health. This assay provides sample results in 30 minutes using a combination of rapid PCR amplification and an electrochemical detection system to diagnose infected patients. Again, the use of PCR and the electrochemical nucleic acid detection system necessitates a sophisticated set-up which is unsuitable for out-of-lab use (US9127308).
- At-home self-tests which could provide rapid results directly to the user without the need to attend a health centre or send samples to a laboratory.
- At-home self-test methods may also reduce the unnecessary use of antibiotics by patients who cannot confirm whether they are infected.
- the technical problem underlying the present invention is the provision of improved means and methods for the detection of amplified pathogen derived nucleic acids.
- the present invention therefore provides means and methods for simple indication or diagnosis that can be done outside of the laboratory at a point-of-care or at-home setting.
- the present invention provides means and methods for the easy and convenient detection of pathogen derived nucleic acids and the management of infections arising from said pathogens.
- a method for detecting a target nucleic acid comprising the steps of: a) amplifying a target nucleic acid providing an amplified nucleic acid; b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid.
- test strip comprises the polycarboxylate polymer or agarose polymer in the form of a nanobead.
- the amplified nucleic acid is detected upon contact with the leuco dye, such that a leaving group (LG) of the leuco dye dissociates and a colour change can be detected under visible light
- the leuco dye is of the general formula (I): wherein R 1 and R 2 are each independently selected from a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbon
- the amplified nucleic acid is determined to be present if a visible light signal is detected where the leuco dye is immobilized.
- the leuco dye of the general formula (I) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
- the amplified nucleic acid is determined to be present if a visible light signal is detected where the nucleophile is immobilized.
- the leuco dye of the general formula (II) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
- the target nucleic acid is amplified by a loop-mediated isothermal amplification (LAMP) method.
- LAMP loop-mediated isothermal amplification
- the amplified nucleic acid is single or double stranded nucleic acid.
- the test strip comprises a control line downstream of the immobilized leuco dye and/or immobilized nucleophile.
- the control line comprises an immobilized 3, 3’, 5, 5’ -tetramethylbenzidine.
- the control line comprises a leuco dye immobilized on bentonite clay.
- the target nucleic acid is bacterial or protozoal DNA.
- the bacterial or protozoal DNA is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- a device or kit for detecting a target nucleic acid wherein the device comprises: a) a compartment for the amplification of a target nucleic acid to give an amplified nucleic acid; b) a leuco dye immobilized on a test strip; and c) a flow path for the amplified nucleic acid to be in contact with the immobilized leuco dye.
- the leuco dye is immobilized on a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
- the test strip comprises the polycarboxylate polymer or agarose in the form of a nanobead.
- the leuco dye is immobilized in a reservoir comprising a liquid medium.
- the leuco dye is of the general formula (I): wherein R 1 and R 2 are each independently selected from a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R 8 , -NO3, -NO2, -CN, hal
- R 1 and R 2 each independently represent a substituted or unsubstituted aryl group
- R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group.
- the device or kit comprises at least two compartments for the amplification of a target nucleic acid, at least two test strips comprising immobilized leuco dye and at least two flow paths to contact the amplified nucleic acid with the immobilized leuco dye.
- a method of diagnosing, and/or prognosing a disease by detecting the presence of a target nucleic acid using the method of any one of embodiments 1 to 19.
- infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- a method of treating an infectious disease comprising administering to a subject identified as having or developing an infectious disease using the method of any one of embodiments 1 to 19 or the device or kit of any one of embodiments 20 to 27 an appropriate treatment for said disease.
- infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- the invention relates to a method for detecting a target nucleic acid, the method comprising the steps of: a) amplifying a target nucleic acid providing an amplified nucleic acid; b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid.
- a target nucleic acid is amplified to provide an amplified nucleic acid.
- target nucleic acid refers to a nucleic acid, preferably RNA or DNA, comprising a sequence known to the skilled person to be comprised in a larger target sequence, for example the genome of a target organism.
- the target sequence is thus a sequence comprised in a target organism.
- the target sequence is a sequence allowing to distinguish between one or more, in particular two or more, in particular three or more, organisms, preferably bacteria or protozoa.
- the target nucleic acid as used herein is uniquely found in a target organism or, at least, is not part of more than one, in particular two or more organisms to be detected using the methods of the invention.
- amplified nucleic acid refers to a nucleic acid product generated by a nucleic acid amplification technique.
- Nucleic acid amplification techniques are known to the skilled person. Such techniques can be broadly categorised into those requiring thermal cycling and isothermal methods. Methods requiring thermal cycling, such as PCR, transcription mediated amplification (TMA) and nucleic acid sequence-based amplification (NASBA), cycle the nucleic acid sequence amplification procedure through different temperatures (e.g., 95°C for denaturation, 45°C to 68°C for primer annealing and 68°C to 72°C for template extension) during each round of amplification, thereby requiring a thermal cycler for the technique.
- TMA transcription mediated amplification
- NASBA nucleic acid sequence-based amplification
- Isothermal nucleic acid amplification techniques include strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), nicking enzyme amplification reaction (NEAR), helicase-dependent amplification (HDA), rolling circle amplification (RCA) and recombinase polymerase amplification (RPA) do not require a thermal cycler.
- SDA strand displacement amplification
- LAMP loop-mediated isothermal amplification
- NEAR nicking enzyme amplification reaction
- HDA helicase-dependent amplification
- RCA rolling circle amplification
- RPA recombinase polymerase amplification
- the amplified nucleic acid is brought into contact with an immobilized leuco dye.
- leuco dye refers to a dye which is able to switch between two chemical forms; one of which is substantially colorless or white when observed in day light - referred to as the “leuco form” of the leuco dye.
- the leuco form of the leuco dye typically reacts with another substance to form a colored dye, the second chemical form of the leuco dye.
- the color-altering phenomenon is typically due to a chemical change, such as through an oxidation reaction.
- leuco dye encompasses both the leuco form and colored form of the leuco dye.
- bringing into contact refers to a step of allowing a chemical interaction to happen between at least two molecules, e.g. a target molecule and a leuco dye.
- this step is meant to allow the interaction between the amplified nucleic acid and an immobilized leuco dye used to determine the presence of a target nucleic acid.
- the interaction may be, but is not limited to, covalent or non-covalent binding, such as ionic binding, coordinate binding, van der Waals binding and/or pi-pi interaction.
- the interaction between the nucleic acid and leuco dye may result in the formation of a complex between the leuco dye and nucleic acid.
- a complex between the leuco dye and nucleic acid is well described in the art, and may involve a reaction between the two, but not necessarily so.
- the formation of this complex may result in a color change that is visible to the naked eye and indicative of the presence of the target nucleic acid.
- the amplified nucleic acid is comprised in a solution which is brought into contact with an immobilized leuco dye.
- detecting under visible light refers to the detection of the presence of a color change by the naked eye under ordinary lighting, preferably without exposure to light other than visible light. It is thus required that the color change of the leuco dye used herein is observable under visible light. As such, detection is simplified and does not require equipment, such as a fluorescence reader commonly employed in other nucleic acid detection methods. By visually observing the presence of a color change, it can be determined whether the amplified nucleic acid and thereby target nucleic acid is present.
- changes in color include changes in the type of color under visible light (visible light wavelength) and changes in the concentration of color (reflectance) but are not limited to these as long as the changes can be detected under visible light.
- exemplary changes in the type of color include, for example, the changes from colorless to green, colorless to blue, colorless to magenta.
- the nucleic acid can also be detected by measuring absorbance in the visible light range. Visible light, as used herein, indicates light at wavelengths of 380 nm to 800 nm. The measurement wavelength can be set appropriately according to the dye. It is also possible to assay the nucleic acid concentration in a sample by absorbance measurement. In addition, when an insoluble precipitate of the dye and nucleic acid is formed, the precipitate can be detected with a filter or membrane, or by centrifugation. A dye of a different color may also be mixed in to make it easier to determine the presence or absence of the nucleic acid.
- an immobilized leuco dye for the detection of an amplified nucleic acid provides surprising benefits over the prior art, in particular it provides a rapid and simple means to determine the presence of a target nucleic acid, for example a target nucleic acid comprised in the genome of a pathogen.
- a target nucleic acid for example a target nucleic acid comprised in the genome of a pathogen.
- the presence of the target nucleic acid can be detected under visible light with minimal equipment, enabling point-of-care and at-home self-test diagnosis of the presence of a pathogen.
- the leuco dye is immobilized, preferably immobilized on a test strip.
- test strip refers to a solid or semi-solid strip comprising a material which allows for capillary flow of a solution along a flow path.
- the material is rectangular, and the flow path is axial, however the size and shape of the material is not particularly limited, as long as it allows for capillary flow.
- the test strip of the present invention may be uniplanar with a single sheet on the test strip, comprising at least one line wherein a leuco dye is immobilized.
- the test strip may be multiplanar and comprise multiple lines on multiple sheets which are in fluid communication for simultaneous assays for the same or different target analytes from the same or different samples.
- the test strip is in fluid communication with the amplification compartment, such that a solution of the amplified nucleic acid may flow along the test strip to at least one line wherein a leuco dye is immobilized.
- a solution of the amplified nucleic acid may flow along the test strip to at least one line wherein a leuco dye is immobilized.
- the leuco dye may be immobilized in a solid or liquid state.
- the immobilization of the leuco dye may be achieved by physical or chemical means. Physical means of immobilization include, adsorption, absorption and entrapment, but are not limited to these methods.
- Chemical immobilization may involve the covalent linkage of the leuco dye to a material comprised on the test strip but is not necessarily limited to covalent linkage.
- the leuco dye is immobilized in a localized and specific line on the test strip, preferably directly downstream of the amplification compartment.
- the inventors of the present invention surprisingly found that the method of the present invention allows for a facile “one-step” detection of an amplified nucleic acid from a target nucleic acid by means of a test strip on which a leuco dye is immobilized. This is particularly advantageous for point-of-care and at-home self-tests for the detection of pathogenic infection.
- the simplistic signal visualization enabled by the use of an immobilized leuco dye on the test strip provides a direct optical readout which can be read and interpreted by the user without the need to consult a healthcare professional.
- the provision of a test strip with an immobilized detecting reagent additionally allows for the test results to be easily recorded and documented.
- Another advantage of the test strip design is the ease of manufacture, storage and handling of devices comprising these elements.
- immobilizing the leuco dye on a test strip improves the stability and shelf-life of the leuco dye, particularly compared to methods where liquid form dyes are employed.
- the leuco dye is immobilized onto a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
- cellulose acetate refers to a fibrous porous material which may comprise a pure cellulose acetate polymer or modified cellulose acetate polymer.
- the fibres of the material may be oriented along a particular axis (i.e., aligned), or they may be random.
- MCE mixed cellulose ester
- polycarboxylate polymer refers to polyanionic macromolecules comprising carboxylate-terminated polymers.
- carboxylate-terminated polymers include, but are not limited to, carboxylated polystyrene, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), various grades of hydroxypropyl methylcellulose phthalate and various grades of methacrylic acid copolymers.
- agarose refers to the neutral gelling fraction of agar, consisting of a linear polymer based on the -(1 - ⁇ 3)-p-D-galactopyranose-(1 — >4)-3,6- anhydro-a-L-galactopyranose units.
- Agarose is typically high in molecular weight, which is about 120,000 and low in sulphate.
- the agarose polymer of the present invention is preferably activated to comprise an aldehyde group which is commonly referred to as an “aldehyde-activated agarose” or “polyaldehyde-activated agarose” in the art.
- aldehyde groups on the agarose polymer allow for the linkage of the polymer to a variety of chemical moieties, including amine groups.
- Alternative activated forms of agarose polymers are well described in the art, and may for example include cyanogen halide activated agarose, N-hydrosuccinimde activated agarose, epoxy activated agarose and amine activated agarose.
- a person skilled in the art is aware of the various activated agarose forms which may be suitable for the present invention.
- chitosan polymer or “chitosan membrane”, as used herein, refers to a linear polysaccharide composed of randomly distributed 0-(1 — >4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit).
- the leuco dye is immobilized on the chitosan polymer by a covalent linkage between the amine of the chitosan polymer and an amino group of the leuco dye.
- the immobilization of the leuco dye on a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer is particularly advantageous to immobilize the leuco dye in a localized line of the test strip.
- the polymer used should allow liquid to flow on or through the strip.
- the test strip of the present invention may use a variety of polymers and materials which should be in fluid flow communication/contact or capable of being brought into fluid flow communication/contact.
- the strip should have sufficient inherent strength or additional strength can be provided by a supplemental support such as a plastic backing upon which porous or bibulous strip components are attached.
- the test strip comprises the polycarboxylate or agarose polymer in the form of a nanobead.
- the polycarboxylate polymer nanobead comprises carboxylated polystyrene or carboxylate-terminated polystyrene.
- the nanobead has a pore size of 0.5 pm, 0.75 pm, 1 .0 pm, 2.0 pm, 3.0 pm, most preferred is a diameter of 3.0 pm, however, the diameter is not particularly limited.
- the agarose nanobeads are aldehyde activated nanobeads with a uniform size in the range of 50 to 150 pm.
- the use of polycarboxylate or agarose polymer nanobeads in the present invention was found to improve the detection performance of the test strip. More specifically, the inventors found that the use of nanobeads prevents leaching and improves the stability of the leuco dye. This is typically achieved by the covalent linkage of the dye to the nanobead but may also be achieved by any other means of chemically or physically immobilizing the leuco to the nanobead.
- nanobeads improves the visibility of the color change, due to the availability of a larger surface area for binding, thus improving the sensitivity of detection assays.
- a further advantage of the use of nanobeads is the potential to tune and optimize the flow rate on the test strip by selecting nanobeads with various pore sizes.
- the leuco dye is immobilized in a reservoir comprising a liquid medium.
- the immobilization of the leuco dye within a reservoir comprised on the test strip may be advantageous for the efficient mixing of the solution of amplified nucleic acid and a solution of leuco dye comprised in a reservoir, thereby potentially optimising the contact made between the leuco dye and amplified nucleic acid which may have an impact on the signal intensity.
- the liquid medium comprising the leuco dye of the present invention may include aqueous solutions such as distilled or purified water or buffer solutions but is not particularly limited.
- the amplified nucleic acid is detected upon contact with the leuco dye, such that a leaving group (LG) of the leuco dye dissociates and a colour change can be detected under visible light
- the leuco dye is of the general formula (I): wherein R 1 and R 2 are each independently selected from a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alky
- the amplified nucleic acid is determined to be present if a visible light signal is detected where the leuco dye is immobilized.
- the inventors of the present invention found that by contacting a nucleic acid with an immobilized leuco dye of general formula (I), a leaving group on the leuco form of the leuco dye dissociates by interaction with the amplified nucleic acid, resulting in a color change that can be detected under visible light.
- the visible signal may be assessed either visually or by optical detection devices, such as a smartphone camera capable of reading storing and transmitting the test result.
- the leuco dye of the general formula (I) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
- methyl green of the general formula (I) is a compound according to formula:
- basic fuchsin of the general formula (I) is a compound according to formula:
- acid fuchsin of the general formula (I) is a compound according to formula:
- crystal violet of the general formula (I) is a compound according to formula:
- malachite green of the general formula (I) is a compound according to formula:
- the positive charge is balanced by a necessary counterion or counterions.
- the counterion(s) may be the counterion(s) indicated hereinabove and represented by the abbreviation LG, however the counterion(s) of the present invention is not particularly limited and may include counterions well described in the art.
- the amplified nucleic acid and leuco dye form a complex which is brought into contact with a nucleophile that is immobilized downstream of the leuco dye
- the leuco dye of the complex is of the general formula (II): wherein R 1 and R 2 each independently represent a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group,
- the amplified nucleic acid is determined to be present if a visible light signal is detected where the nucleophile is immobilized.
- the inventors of the present invention found that contacting a leuco dye of general formula (II) with the amplified nucleic acid results in the formation of a complex, which can then be contacted with a nucleophile downstream of the immobilized leuco dye. In the presence of the leuco dye nucleic acid complex, a visible light signal in the form of a color change is observed where the nucleophile is immobilized.
- the dye of general formula (II) when the dye of general formula (II) is contacted with the target nucleic acid solution prior to the onset of the amplification reaction, the dye of general formula (II), may, in some embodiments, change color (e.g., change from a colored form to a colorless form) as a result of a reaction with a compound comprised in the solution, for example, Tris comprised in a buffer solution (or any other basic compounds comprised in e.g., buffer solutions that are well known to the skilled person).
- the reaction of the dye of general formula (II) with a compound comprised in the buffer can result in the formation of a compound of general formula (I), where LG is comprised of the compound comprised in the solution.
- the amplicons then react with the compound of general formula (I), resulting in the dissociation of the LG and a change in color.
- this reaction is typically slow taking around 60 minutes for the color change to be detected under visible light.
- the reaction with a compound comprised in the solution, e.g., the buffer solution, does not take place and a nucleic acid-dye of formula (II) complex is formed which may flow downstream to a location where the nucleophile is immobilized.
- nucleic acid-dye of formula (II) i.e., when the pathogen is present in the sample and amplification has taken place
- a color change may be observed due to the reaction of the nucleic acid-dye of formula (II) complex and nucleophile.
- contact between the solution comprising the sample and the dye of general formula (II) may result in the reaction of said dye with a compound comprised in said solution, resulting in the formation of a compound of general formula (I).
- the compound of general formula (I) is contacted with an immobilised nucleophile, no color change is observed under visible light.
- the leuco dye of the general formula (II) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
- methyl green of the general formula (II) is a compound according to formula:
- basic fuchsin of the general formula (II) is a compound according to formula:
- acid fuchsin of the general formula (II) is a compound according to formula:
- crystal violet of the general formula (II) is a compound according to formula:
- malachite green of the general formula (II) is a compound according to formula:
- the positive charge is balanced by a necessary counterion or counterions.
- the counterion(s) may be the counterion(s) indicated hereinabove and represented by the abbreviation LG, however the counterion(s) of the present invention is not particularly limited and may include counterions well described in the art.
- the target nucleic acid is amplified by a loop- mediated isothermal amplification (LAMP) method.
- LAMP loop- mediated isothermal amplification
- the LAMP method uses 6 primer oligonucleotides comprising a forward outer primer (F3), backward outer primer (B3), forward inner primer (FIP), backward inner primer (BIP), loop primer forward (LF) and loop primer backward (LB) and a polymerase with strand displacement activity to identify a target region on the target nucleic acid.
- F3 and B3 primers are strand invasion oligonucleotides used for the elongation step.
- the addition of loop primers significantly accelerates amplification, increasing sensitivity and reducing reaction time.
- the inventors of the present invention found that amplification of the target nucleic acid by a LAMP method is advantageous since it does not require thermal cycling which necessitates large and complicated equipment to produce detectable amounts of amplified nucleic acid. It is well understood in the art that the LAMP method is a highly sensitive and specific diagnostic method. The use of the LAMP method therefore is well suited for point-of-care and at-home self-tests, which require that the method is fast, efficient and useable by non-medical professionals.
- the target nucleic acid is DNA or RNA.
- the amplified nucleic acid is single or double stranded nucleic acid.
- the test strip comprises a control line downstream of the immobilized leuco dye and/or immobilized nucleophile.
- control line refers to a region of the test strip, generally downstream of the test line(s), which is used to indicate that the sample has flowed through the test line(s).
- control line comprises one or more immobilized reagents capable of providing an indication that the sample has passed through the test lines.
- the control line provides a visible signal upon contact with the sample.
- the present invention may comprise at least one, and optionally more control lines, but does not necessarily do so.
- control line comprises an immobilized 3, 3’, 5,5’- tetramethylbenzidine.
- Immobilized 3,3’,5,5’-tetramethylbenzidine is a typical reagent used for control lines on test strips.
- TMB is oxidised by the enzyme horseradish peroxidase, which produces a visible color change from colorless to blue.
- the primers used for the amplification of the target nucleic acid would comprise horseradish peroxidase, thereby producing amplified nucleic acids containing horseradish peroxidase.
- Post-amplified samples containing horseradish peroxidase which flow to the control line react with TMB and provide a visible signal that the sample has flowed through the test strip and test lines(s).
- TMB is immobilized on a cellulose acetate, mixed cellulose ester or chitosan polymer.
- the immobilization may be, but is not limited to, chemical immobilization via covalent bond formation, or physical immobilization via adsorption or absorption.
- control line comprises a leuco dye immobilized on bentonite clay.
- bentonite clay refers to an absorbent swelling clay comprising mainly of montmorillonite - a soft phyllosilicate group of minerals.
- a solid mixture comprising the bentonite clay and leuco dye immobilized on a test strip may act as reagents capable of providing a visible signal on the control line.
- a control line comprising a mixture of bentonite clay and leuco dye provides a visible signal upon contact with a sample solution indicating that a leaving group on the leuco dye dissociates upon interaction with the solution. A color change is observed irrespective of whether the sample contains the amplified nucleic acid.
- the target nucleic acid is bacterial or protozoal DNA.
- the bacterial or protozoal DNA is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- the method of the present invention is particularly suitable for the detection of target nucleic acids derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
- the method of the present invention therefore provides a simple and efficient means for detecting a signal from the nucleic acid originating from a sexually transmitted pathogenic organism and indicating to the user whether or not they have been infected.
- the invention provides a device or kit for detecting a target nucleic acid, wherein the device comprises: a) a compartment for the amplification of a target nucleic acid to give an amplified nucleic acid, b) a leuco dye immobilized on a test strip, c) a flow path for the amplified nucleic acid to be in contact with the immobilized leuco dye.
- the material of the container is not particularly limited but may for example be comprised of a plastic material.
- the amplification compartment is in fluidic communication with the test strip, to enable the detection of the amplified nucleic acid.
- the device of the present invention will be suitable for providing a "one-step" detection of nucleic acids derived from pathogens causing STIs.
- the amplified sample may be flowed through the test strip to provide a visual signal which directly indicates the presence or absence of a pathogen derived nucleic acid, without performing any additional steps.
- the device or kit of the invention contains a leuco dye which is immobilized on a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
- the device or kit contains a test strip comprising the polycarboxylate polymer or agarose in the form of a nanobead.
- the leuco dye is immobilized in a reservoir comprising a liquid medium.
- the leuco dye is of the general formula (I): wherein R 1 and R 2 are each independently selected from a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R 8 , -NO3, -NO2, -CN, halogen, -NHR
- the leuco dye is of the general formula (II): wherein R 1 and R 2 each independently represent a substituted or unsubstituted aryl group; R 3 , R 4 , R 5 , R 6 , R 7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group.
- the device or kit comprises at least two compartments for the amplification of a target nucleic acid, at least two test strips comprising immobilized leuco dye and at least two flow paths to contact the amplified nucleic acid with the immobilized leuco dye.
- the target nucleic acid may be comprised in a sample obtained from a human subject (e.g. tissue sample, bronchoalveolar lavage, bronchial wash, pharyngeal exudate, tracheal aspirate, blood, serum, plasma, bone, skin, soft tissue, intestinal tract specimen, genital tract specimen, breast milk, lymph, cerebrospinal fluid, pleural fluid, sputum, urine, a nasal secretion, tears, bile, ascites fluid, pus, synovial fluid, vitreous fluid, vaginal secretion, semen and/or urethral tissue).
- the sample comprising the target nucleic acid is obtained from urine, urethral swab, endocervical swab or vaginal swab.
- Figure 1 Shows the basic concept of the device of the present invention comprising a LAMP compartment (or well) and a lateral flow test strip with a test zone and control zone.
- the test zone herein would comprise an immobilized leuco dye of general formula (I), wherein a leaving group of the leuco dye dissociates upon interaction with the amplified nucleic acid. The interaction of the leuco dye and nucleic acid would produce a visible light signal.
- Figure 2 Shows the basic concept of the device of the present invention comprising a LAMP compartment (or well) and a lateral flow test strip with two test zones and control zone.
- the first test zone comprises the leuco dye of general formula (II) which forms a complex with the amplified nucleic acid, the solution of which then flows downstream to a second test zone comprising an immobilized nucleophile.
- a visible light signal where the nucleophile is immobilized indicates the presence or absence of the amplified nucleic acid.
- Figure 3 Shows the immobilization of basic fuchsin on a chitosan polymer.
- a strip of polymeric material was dipped into a solution of leuco-dye and was allowed to incubate for 15- 30 min at room temperature. Subsequently, the polymeric membrane was removed and allowed to dry for another 30 min. Note that the polymeric material may gain the colour of the leuco-dye.
- Polycarboxylate nanobeads were added to a solution of methyl green-sodium sulfite based leuco-dye. The mixture was allowed to incubate for 15-30 min at room temperature. Subsequently, the polycarboxylate nanobeads were allowed to dry for another 30 min. Note that here methyl green-sodium sulfite leuco-dye (of general formula (I)) is colourless therefore, the polycarboxylate nanobeads retain their initial colour.
- a Functionalized polymeric material is conjugated to a functionalized dye through a chemical reaction. Subsequently, the obtained polymeric material is reacted to a nucleophile (e.g., sodium sulfite) resulting in a chemically immobilized leuco-dye.
- a nucleophile e.g., sodium sulfite
- the product can be purified in several ways including washing accompanied by centrifugation.
- Chitosan (1.2 g) was dissolved in 60 mL (2% acetic acid) solution in a 150 mL Erlenmeyer flask equipped with a Teflon-coated magnetic stir bar. The solution was stirred for 30 min at RT followed by addition of basic fuchsin (470 l_, 5.1 x 10 -3 mmol) to the light yellow viscous chitosan solution whilst stirring for 30 min further. Acetaldehyde (285 L, 5.1 x 1 O ⁇ 3 mmol) was added to the mixture, and a white low-viscous solution was formed. The reaction mixture was stirred at 70 °C for 18 h.
- basic fuchsin 470 l_, 5.1 x 10 -3 mmol
- strip 1 A strip of polymeric material with the immobilized leuco-dye of general formula (I) (strip 1) was brought into contact with solution containing the target nucleic acids.
- strip R Another strip of polymeric material with immobilized leuco-dye of general formula (I) (strip R) was dipped into a solution without the target nucleic acids as a control.
- Strip 1 changed its colour indicating the presence of the target nucleic acids in the solution while strip R retained its initial colour.
- a white coloured cellulose acetate strip with the immobilized methyl green-sodium sulfite leuco-dye of general formula (I) (strip 1) was brought into contact with a solution containing target nucleic acids.
- Another white coloured cellulose acetate strip with immobilized methyl green leuco-dye of general formula (I) (strip R) was brought into contact with a solution without the target nucleic acids as a control.
- Strip 1 changed its colour to blue indicating the presence of target nucleic acids in the solution while strip R remained white coloured.
- the leuco dye 100 uL
- the leuco-dye & nanobead mixture was spread on a cellulose acetate membrane and allowed to dry at room temperature for 1 h. Caution should be taken to not allow the nanobeads to dry prior to spreading it onto a cellulose acetate membrane. If the nanobeads are left to dry without spreading on a cellulose acetate membrane (i.e., the cellulose acetate seems important to keep the color intac)t. Subsequently, the nanobead & cellulose acetate membrane is attached to a lateral flow setup and tested for DNA detection.
Abstract
The application, inter alia, provides a method for detecting a target nucleic acid, the method comprising the steps of (a) amplifying a target nucleic acid providing an amplified nucleic acid; (b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and (c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid. In some embodiments, the target nucleic acid is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. The present invention thus also relates to methods for determining whether a subject suffers from an infection caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis and associated diseases.
Description
Colorimetric Nucleic Acid Detection
The application, inter alia, provides a method for detecting a target nucleic acid, the method comprising the steps of (a) amplifying a target nucleic acid providing an amplified nucleic acid; (b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and (c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid. In some embodiments, the target nucleic acid is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. The present invention thus also relates to methods for determining whether a subject suffers from an infection caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis and associated diseases.
Sexually transmitted infections (STIs) are among the most common infectious diseases globally and are associated with significant morbidity and mortality worldwide. According to the World Health Organization (WHO), more than 1 million STIs are acquired every day worldwide. In 2020, the WHO estimated that 374 million new infections were reported for one of four of the following STIs: chlamydia (129 million), gonorrhoea (82 million), syphilis (7.1 million) and trichomoniasis (156 million). Approximately 80% of the newly reported STI cases occur in developing countries, and disproportionately impact women. Since many infected individuals present as asymptomatic, STIs may go undetected for a long time leading to their further spread. If left untreated, STIs can lead to more severe consequences than the initial symptoms of the infection, including blindness, bone deformities, brain damage, cancer, heart disease, long-term reproductive complications, birth defects, and even death. Early and accurate diagnosis of infection is therefore essential to limit the spread and outcomes of the infection and provide patients with timely, appropriate, and effective treatment.
Accurate and reliable diagnostic tests for STIs are widely available in high-income countries and typically provided by healthcare professionals. These tests usually involve a physical examination and laboratory testing of blood, urine and/or swab samples. Given the resources needed for such tests, they remain largely unavailable in developing countries. Moreover, testing facilities in developing countries can be geographically inaccessible and expensive, with results being significantly delayed. There is therefore an urgent and unmet need to provide universally accessible and inexpensive STI testing means.
Point-of-care tests have the potential to transform the prevention and control of STIs by enabling immediate diagnosis and early treatment of infections. Currently, there are several point-of-care tests available for the diagnosis of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis infections, although these tests differ regarding their performance, turnaround time and cost.
The U.S. Food and Drug Administration has currently cleared three rapid tests for chlamydia and gonorrhoea and two for trichomonas. The Xpert® CT/NG assay, produced by Cepheid® is anFDA cleared rapid test for Chlamydia and gonorrhoea, however it has not been waived by the Clinical Laboratory Improvement Amendments (CLIA). This is a cartridge-based assay, relying on molecular Nucleic Acid Amplification Technology (NAATs), which is able to detect nucleic acids from pathogens. The Xpert cartridge combines microfluidic technology with real-time polymerase chain reaction (qPCR) allowing for amplification and detection in 90 minutes. Given the use qPCR, which involves thermocycling and a complex amplification process, the Xpert device is large, cumbersome and expensive, making it unsuitable for resource-limited settings.
A second FDA approved and CLIA waived assay for chlamydia and gonorrhoea is the io device produced by binx health. This assay provides sample results in 30 minutes using a combination of rapid PCR amplification and an electrochemical detection system to diagnose infected patients. Again, the use of PCR and the electrochemical nucleic acid detection system necessitates a sophisticated set-up which is unsuitable for out-of-lab use (US9127308).
Beyond point-of-care tests, one area of technology which has the potential to revolutionize STI testing is the development of at-home self-tests, which could provide rapid results directly to the user without the need to attend a health centre or send samples to a laboratory. Currently, there are no products on the market capable of providing such rapid results at home. One obstacle in the development of such technology is the ability to detect amplified pathogen derived nucleic acids in a few simple steps using minimal equipment that is affordable, convenient and user friendly. At-home self-test methods may also reduce the unnecessary use of antibiotics by patients who cannot confirm whether they are infected.
Traditionally, post-amplified nucleic acids are detected using electrophoresis, a labour-intensive manual processing and instrumentation method. More recent developments provide alternative detection methods, e.g., fluorescence detection of double-stranded DNA (dsDNA) with an intercalating or magnesium-sensitive fluorophore; bioluminescence through pyrophosphate conversion; or turbidity detection of precipitated magnesium pyrophosphate. However, these visual methods typically require long incubation times (> 60 minutes), specific instruments for detection, or are too subtle in the change of signal for robust detection outside of the laboratory. Moreover, the currently available methods require several steps, often executed by the user, before a signal is generated. The current methods may therefore be difficult to use and lead to errors when operated by non-professionals.
There is therefore a need for a simple, user-friendly, reliable, rapid and inexpensive method for the detection of amplified pathogen derived nucleic acids.
Thus, the technical problem underlying the present invention is the provision of improved means and methods for the detection of amplified pathogen derived nucleic acids. The present invention therefore provides means and methods for simple indication or diagnosis that can be done outside of the laboratory at a point-of-care or at-home setting. Furthermore, the present invention provides means and methods for the easy and convenient detection of pathogen derived nucleic acids and the management of infections arising from said pathogens.
The above technical problem is solved by the embodiments provided herein and as characterised in the claims. Accordingly, the present invention relates to, inter alia, the following embodiments:
1 . A method for detecting a target nucleic acid, the method comprising the steps of: a) amplifying a target nucleic acid providing an amplified nucleic acid; b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid.
2. The method according to embodiment 1 , wherein the leuco dye is immobilized on a test strip.
3. The method according to embodiment 1 or 2, wherein the leuco dye is immobilized onto a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
4. The method according to embodiment 3, wherein the test strip comprises the polycarboxylate polymer or agarose polymer in the form of a nanobead.
5. The method according to embodiment 1 or 2, wherein the leuco dye is immobilized in a reservoir comprising a liquid medium.
6. The method according to any one of embodiments 1 to 5, wherein the amplified nucleic acid is detected upon contact with the leuco dye, such that a leaving group (LG) of the leuco dye dissociates and a colour change can be detected under visible light, wherein the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group,
alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10 ) (COR11 ), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group. The method according to embodiment 6, wherein the amplified nucleic acid is determined to be present if a visible light signal is detected where the leuco dye is immobilized. The method according to embodiment 6 or 7, wherein the leuco dye of the general formula (I) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof. The method according to any one of embodiments 1 to 5, wherein the amplified nucleic acid and leuco dye form a complex which is brought into contact with a nucleophile that is immobilized downstream of the leuco dye, wherein the leuco dye of the complex is of the general formula (II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group, and/or wherein the immobilized nucleophile comprises sulfite ions, hydrogen sulfite ions, nitrate ions, nitrite ions, cyanide ions, halide ions, nitrogen nucleophiles, sulfur nucleophiles, alkali metal alkoxides, alkali metal hydroxides or hydride nucleophiles. The method according to embodiment 9, wherein the amplified nucleic acid is determined to be present if a visible light signal is detected where the nucleophile is immobilized.
The method according to embodiment 9 or 10, wherein the leuco dye of the general formula (II) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof. The method according to any one of embodiments 1 to 11 , wherein the target nucleic acid is amplified by a loop-mediated isothermal amplification (LAMP) method. The method according to any one of embodiments 1 to 12, wherein the target nucleic acid is DNA or RNA. The method according to any one of embodiments 1 to 13, wherein the amplified nucleic acid is single or double stranded nucleic acid. The method according to any one of embodiments 2 to 14, wherein the test strip comprises a control line downstream of the immobilized leuco dye and/or immobilized nucleophile. The method according to embodiment 15, wherein the control line comprises an immobilized 3, 3’, 5, 5’ -tetramethylbenzidine. The method according to embodiment 15, wherein the control line comprises a leuco dye immobilized on bentonite clay. The method according to any one of embodiments 1 to 17, wherein the target nucleic acid is bacterial or protozoal DNA. The method according to embodiment 18, wherein the bacterial or protozoal DNA is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. A device or kit for detecting a target nucleic acid, wherein the device comprises: a) a compartment for the amplification of a target nucleic acid to give an amplified nucleic acid; b) a leuco dye immobilized on a test strip; and c) a flow path for the amplified nucleic acid to be in contact with the immobilized leuco dye. The device or kit according to embodiment 20, wherein the leuco dye is immobilized on a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
The device or kit according to embodiment 20 or 21 , wherein the test strip comprises the polycarboxylate polymer or agarose in the form of a nanobead. The device or kit according to embodiment 20, wherein the leuco dye is immobilized in a reservoir comprising a liquid medium. The device or kit according to any one of embodiments 20 to 23, wherein the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10 ) (COR11 ), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group. The device or kit according to embodiment 24, wherein a signal is generated where the leuco dye is immobilized by contact between the leuco dye and amplified nucleic acid. The device or kit according to embodiment 20 to 23, wherein the leuco dye is of the general formula
(II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group,
ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group.
27. The device or kit according to any one of embodiments 20 to 26, wherein the device or kit comprises at least two compartments for the amplification of a target nucleic acid, at least two test strips comprising immobilized leuco dye and at least two flow paths to contact the amplified nucleic acid with the immobilized leuco dye.
28. A method of diagnosing, and/or prognosing a disease by detecting the presence of a target nucleic acid using the method of any one of embodiments 1 to 19.
29. The method of embodiment 28, wherein the disease is an infectious disease.
30. The method of embodiment 29, wherein the infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
31. A method of treating an infectious disease, wherein the method comprises administering to a subject identified as having or developing an infectious disease using the method of any one of embodiments 1 to 19 or the device or kit of any one of embodiments 20 to 27 an appropriate treatment for said disease.
32. The method of embodiment 31, wherein the infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
Accordingly, in a first embodiment, the invention relates to a method for detecting a target nucleic acid, the method comprising the steps of: a) amplifying a target nucleic acid providing an amplified nucleic acid; b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid.
As such, in a first step of the method of the invention, a target nucleic acid is amplified to provide an amplified nucleic acid.
The term “target nucleic acid”, as used herein, refers to a nucleic acid, preferably RNA or DNA, comprising a sequence known to the skilled person to be comprised in a larger target sequence, for example the genome of a target organism. In one embodiment, the target sequence is thus a sequence
comprised in a target organism. It is preferred that the target sequence is a sequence allowing to distinguish between one or more, in particular two or more, in particular three or more, organisms, preferably bacteria or protozoa. As such, it is preferred that the target nucleic acid as used herein is uniquely found in a target organism or, at least, is not part of more than one, in particular two or more organisms to be detected using the methods of the invention.
The term "amplified nucleic acid", as used herein, refers to a nucleic acid product generated by a nucleic acid amplification technique. Nucleic acid amplification techniques are known to the skilled person. Such techniques can be broadly categorised into those requiring thermal cycling and isothermal methods. Methods requiring thermal cycling, such as PCR, transcription mediated amplification (TMA) and nucleic acid sequence-based amplification (NASBA), cycle the nucleic acid sequence amplification procedure through different temperatures (e.g., 95°C for denaturation, 45°C to 68°C for primer annealing and 68°C to 72°C for template extension) during each round of amplification, thereby requiring a thermal cycler for the technique. Isothermal nucleic acid amplification techniques include strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), nicking enzyme amplification reaction (NEAR), helicase-dependent amplification (HDA), rolling circle amplification (RCA) and recombinase polymerase amplification (RPA) do not require a thermal cycler. Within the present invention, an isothermal amplification method is preferred. In particular, it is preferred that a LAMP method is used to obtain the amplified nucleic acid in the methods of the invention.
In a second step, subsequent to the step of amplifying a target nucleic acid providing an amplified nucleic acid, the amplified nucleic acid is brought into contact with an immobilized leuco dye.
The term “leuco dye”, as used herein, refers to a dye which is able to switch between two chemical forms; one of which is substantially colorless or white when observed in day light - referred to as the “leuco form” of the leuco dye. The leuco form of the leuco dye typically reacts with another substance to form a colored dye, the second chemical form of the leuco dye. The color-altering phenomenon is typically due to a chemical change, such as through an oxidation reaction. It is to be understood that the term leuco dye, as used herein, encompasses both the leuco form and colored form of the leuco dye. An example of the transformation of a leuco dye from the leuco form to a colored dye is given herein below:
Leuco form Colored dye
The term “bringing into contact”, or grammatical variations thereof, as used herein, refers to a step of allowing a chemical interaction to happen between at least two molecules, e.g. a target molecule and a leuco dye. Within the present invention, this step is meant to allow the interaction between the
amplified nucleic acid and an immobilized leuco dye used to determine the presence of a target nucleic acid. The interaction may be, but is not limited to, covalent or non-covalent binding, such as ionic binding, coordinate binding, van der Waals binding and/or pi-pi interaction. The interaction between the nucleic acid and leuco dye may result in the formation of a complex between the leuco dye and nucleic acid. The formation of a complex between the leuco dye and nucleic acid is well described in the art, and may involve a reaction between the two, but not necessarily so. The formation of this complex may result in a color change that is visible to the naked eye and indicative of the presence of the target nucleic acid.
In one embodiment of the invention, the amplified nucleic acid is comprised in a solution which is brought into contact with an immobilized leuco dye.
The term, “detecting under visible light”, or grammatical variations thereof, as used herein, refers to the detection of the presence of a color change by the naked eye under ordinary lighting, preferably without exposure to light other than visible light. It is thus required that the color change of the leuco dye used herein is observable under visible light. As such, detection is simplified and does not require equipment, such as a fluorescence reader commonly employed in other nucleic acid detection methods. By visually observing the presence of a color change, it can be determined whether the amplified nucleic acid and thereby target nucleic acid is present. Specific examples of changes in color include changes in the type of color under visible light (visible light wavelength) and changes in the concentration of color (reflectance) but are not limited to these as long as the changes can be detected under visible light. Exemplary changes in the type of color include, for example, the changes from colorless to green, colorless to blue, colorless to magenta.
The nucleic acid can also be detected by measuring absorbance in the visible light range. Visible light, as used herein, indicates light at wavelengths of 380 nm to 800 nm. The measurement wavelength can be set appropriately according to the dye. It is also possible to assay the nucleic acid concentration in a sample by absorbance measurement. In addition, when an insoluble precipitate of the dye and nucleic acid is formed, the precipitate can be detected with a filter or membrane, or by centrifugation. A dye of a different color may also be mixed in to make it easier to determine the presence or absence of the nucleic acid.
The inventors of the present invention found that the use of an immobilized leuco dye for the detection of an amplified nucleic acid provides surprising benefits over the prior art, in particular it provides a rapid and simple means to determine the presence of a target nucleic acid, for example a target nucleic acid comprised in the genome of a pathogen. Conveniently, within the methods of the present invention, the presence of the target nucleic acid can be detected under visible light with minimal equipment, enabling point-of-care and at-home self-test diagnosis of the presence of a pathogen.
Accordingly, within the present invention, the leuco dye is immobilized, preferably immobilized on a test strip.
The term “test strip”, as used herein, refers to a solid or semi-solid strip comprising a material which allows for capillary flow of a solution along a flow path. Generally, the material is rectangular, and the flow path is axial, however the size and shape of the material is not particularly limited, as long as it
allows for capillary flow. The test strip of the present invention may be uniplanar with a single sheet on the test strip, comprising at least one line wherein a leuco dye is immobilized. Alternatively, the test strip may be multiplanar and comprise multiple lines on multiple sheets which are in fluid communication for simultaneous assays for the same or different target analytes from the same or different samples. In preferred embodiments of the invention, the test strip is in fluid communication with the amplification compartment, such that a solution of the amplified nucleic acid may flow along the test strip to at least one line wherein a leuco dye is immobilized. Once the amplified nucleic acid solution flows to the line where the leuco dye is immobilized, a complex is formed between the leuco dye and amplified nucleic acid, which may or may not result in a color change where the leuco dye is immobilized.
The term “immobilized on a test strip”, or grammatical variations thereof, as used herein, refers to the immobilization of a leuco dye on the solid or semi-solid test strip as defined hereinabove. The leuco dye may be immobilized in a solid or liquid state. The immobilization of the leuco dye may be achieved by physical or chemical means. Physical means of immobilization include, adsorption, absorption and entrapment, but are not limited to these methods. Chemical immobilization may involve the covalent linkage of the leuco dye to a material comprised on the test strip but is not necessarily limited to covalent linkage. Furthermore, in preferred embodiments of the invention, the leuco dye is immobilized in a localized and specific line on the test strip, preferably directly downstream of the amplification compartment.
The inventors of the present invention surprisingly found that the method of the present invention allows for a facile “one-step” detection of an amplified nucleic acid from a target nucleic acid by means of a test strip on which a leuco dye is immobilized. This is particularly advantageous for point-of-care and at-home self-tests for the detection of pathogenic infection. The simplistic signal visualization enabled by the use of an immobilized leuco dye on the test strip provides a direct optical readout which can be read and interpreted by the user without the need to consult a healthcare professional. The provision of a test strip with an immobilized detecting reagent additionally allows for the test results to be easily recorded and documented. Another advantage of the test strip design is the ease of manufacture, storage and handling of devices comprising these elements. Furthermore, immobilizing the leuco dye on a test strip improves the stability and shelf-life of the leuco dye, particularly compared to methods where liquid form dyes are employed.
In a further preferred embodiment of the invention, the leuco dye is immobilized onto a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
The term “cellulose acetate”, as used herein, refers to a fibrous porous material which may comprise a pure cellulose acetate polymer or modified cellulose acetate polymer. The fibres of the material may be oriented along a particular axis (i.e., aligned), or they may be random.
The term “mixed cellulose ester (MCE)”, as used herein, refers to membrane filters that are composed of a mixture of cellulose nitrate and cellulose acetate. MCE materials are naturally hydrophilic
and offer a high degree of internal surface area with uniform pore structure which provides consistent flow and diffusion rates.
The term “polycarboxylate polymer”, as used herein, refers to polyanionic macromolecules comprising carboxylate-terminated polymers. Examples of carboxylate-terminated polymers include, but are not limited to, carboxylated polystyrene, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), various grades of hydroxypropyl methylcellulose phthalate and various grades of methacrylic acid copolymers.
The term "agarose", as used herein, refers to the neutral gelling fraction of agar, consisting of a linear polymer based on the -(1 -^3)-p-D-galactopyranose-(1 — >4)-3,6- anhydro-a-L-galactopyranose units. Agarose is typically high in molecular weight, which is about 120,000 and low in sulphate. The agarose polymer of the present invention is preferably activated to comprise an aldehyde group which is commonly referred to as an “aldehyde-activated agarose” or “polyaldehyde-activated agarose” in the art. The provision of aldehyde groups on the agarose polymer allow for the linkage of the polymer to a variety of chemical moieties, including amine groups. Alternative activated forms of agarose polymers are well described in the art, and may for example include cyanogen halide activated agarose, N-hydrosuccinimde activated agarose, epoxy activated agarose and amine activated agarose. A person skilled in the art is aware of the various activated agarose forms which may be suitable for the present invention.
The term “chitosan polymer” or “chitosan membrane”, as used herein, refers to a linear polysaccharide composed of randomly distributed 0-(1 — >4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). In preferred embodiments of the invention, the leuco dye is immobilized on the chitosan polymer by a covalent linkage between the amine of the chitosan polymer and an amino group of the leuco dye.
Within the present invention, it was found that the immobilization of the leuco dye on a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer is particularly advantageous to immobilize the leuco dye in a localized line of the test strip. Generally, the polymer used should allow liquid to flow on or through the strip. It should be understood that the test strip of the present invention may use a variety of polymers and materials which should be in fluid flow communication/contact or capable of being brought into fluid flow communication/contact. The strip should have sufficient inherent strength or additional strength can be provided by a supplemental support such as a plastic backing upon which porous or bibulous strip components are attached.
In some embodiments of the invention, the test strip comprises the polycarboxylate or agarose polymer in the form of a nanobead.
In preferred embodiments of the invention, the polycarboxylate polymer nanobead comprises carboxylated polystyrene or carboxylate-terminated polystyrene. In further preferred embodiments, the nanobead has a pore size of 0.5 pm, 0.75 pm, 1 .0 pm, 2.0 pm, 3.0 pm, most preferred is a diameter of 3.0 pm, however, the diameter is not particularly limited.
In another preferred embodiment of the invention, the agarose nanobeads are aldehyde activated nanobeads with a uniform size in the range of 50 to 150 pm.
The use of polycarboxylate or agarose polymer nanobeads in the present invention was found to improve the detection performance of the test strip. More specifically, the inventors found that the use of nanobeads prevents leaching and improves the stability of the leuco dye. This is typically achieved by the covalent linkage of the dye to the nanobead but may also be achieved by any other means of chemically or physically immobilizing the leuco to the nanobead. Furthermore, the use of nanobeads improves the visibility of the color change, due to the availability of a larger surface area for binding, thus improving the sensitivity of detection assays. A further advantage of the use of nanobeads is the potential to tune and optimize the flow rate on the test strip by selecting nanobeads with various pore sizes.
In some embodiments of the invention, the leuco dye is immobilized in a reservoir comprising a liquid medium.
Within the present invention, the immobilization of the leuco dye within a reservoir comprised on the test strip may be advantageous for the efficient mixing of the solution of amplified nucleic acid and a solution of leuco dye comprised in a reservoir, thereby potentially optimising the contact made between the leuco dye and amplified nucleic acid which may have an impact on the signal intensity. The liquid medium comprising the leuco dye of the present invention may include aqueous solutions such as distilled or purified water or buffer solutions but is not particularly limited.
In some embodiments, it is preferred that the amplified nucleic acid is detected upon contact with the leuco dye, such that a leaving group (LG) of the leuco dye dissociates and a colour change can be detected under visible light, wherein the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10)(COR11), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group.
In some embodiments of the present invention, the amplified nucleic acid is determined to be present if a visible light signal is detected where the leuco dye is immobilized.
The inventors of the present invention found that by contacting a nucleic acid with an immobilized leuco dye of general formula (I), a leaving group on the leuco form of the leuco dye dissociates by interaction with the amplified nucleic acid, resulting in a color change that can be detected under visible light. The visible signal may be assessed either visually or by optical detection devices, such as a smartphone camera capable of reading storing and transmitting the test result.
In preferred embodiments of the invention, the leuco dye of the general formula (I) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
As preferably understood herein, methyl green of the general formula (I) is a compound according to formula:
As preferably understood herein, basic fuchsin of the general formula (I) is a compound according to formula:
As preferably understood herein, acid fuchsin of the general formula (I) is a compound according to formula:
As preferably understood herein, crystal violet of the general formula (I) is a compound according to formula:
As preferably understood herein, malachite green of the general formula (I) is a compound according to formula:
Where an overall positive charge possessed by the compounds of general formula (I), particularly methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof, the positive charge is balanced by a necessary counterion or counterions. The counterion(s) may be the counterion(s) indicated hereinabove and represented by the abbreviation LG, however the counterion(s) of the present invention is not particularly limited and may include counterions well described in the art.
In further embodiments of the present invention, the amplified nucleic acid and leuco dye form a complex which is brought into contact with a nucleophile that is immobilized downstream of the leuco dye, wherein the leuco dye of the complex is of the general formula (II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group, and/or wherein the immobilized nucleophile comprises sulfite ions, hydrogen sulfite ions, nitrate ions, nitrite ions, cyanide ions, halide
ions, nitrogen nucleophiles, sulfur nucleophiles, alkali metal alkoxides, alkali metal hydroxides or hydride nucleophiles.
In further embodiments of the present invention, the amplified nucleic acid is determined to be present if a visible light signal is detected where the nucleophile is immobilized.
The inventors of the present invention found that contacting a leuco dye of general formula (II) with the amplified nucleic acid results in the formation of a complex, which can then be contacted with a nucleophile downstream of the immobilized leuco dye. In the presence of the leuco dye nucleic acid complex, a visible light signal in the form of a color change is observed where the nucleophile is immobilized.
The inventors of the present invention have found that when the dye of general formula (II) is contacted with the target nucleic acid solution prior to the onset of the amplification reaction, the dye of general formula (II), may, in some embodiments, change color (e.g., change from a colored form to a colorless form) as a result of a reaction with a compound comprised in the solution, for example, Tris comprised in a buffer solution (or any other basic compounds comprised in e.g., buffer solutions that are well known to the skilled person). The reaction of the dye of general formula (II) with a compound comprised in the buffer can result in the formation of a compound of general formula (I), where LG is comprised of the compound comprised in the solution. Once amplification of the target nucleic acid has taken place, the amplicons then react with the compound of general formula (I), resulting in the dissociation of the LG and a change in color. However, this reaction is typically slow taking around 60 minutes for the color change to be detected under visible light. In embodiments where the dye is immobilized, and the amplification takes place (providing the amplified nucleic acid) prior to contacting the dye of general formula (II), the reaction with a compound comprised in the solution, e.g., the buffer solution, does not take place and a nucleic acid-dye of formula (II) complex is formed which may flow downstream to a location where the nucleophile is immobilized. In preferred embodiments, once the nucleic acid-dye of formula (II) (i.e., when the pathogen is present in the sample and amplification has taken place) is in contact with the immobilized nucleophile a color change may be observed due to the reaction of the nucleic acid-dye of formula (II) complex and nucleophile. In some embodiments, when the target nucleic acid is not present in the sample and amplification does not take place, contact between the solution comprising the sample and the dye of general formula (II) may result in the reaction of said dye with a compound comprised in said solution, resulting in the formation of a compound of general formula (I). In preferred embodiments, when the compound of general formula (I) is contacted with an immobilised nucleophile, no color change is observed under visible light.
In preferred embodiments of the present invention, the leuco dye of the general formula (II) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof.
As preferably understood herein, methyl green of the general formula (II) is a compound according to formula:
As preferably understood herein, basic fuchsin of the general formula (II) is a compound according to formula:
As preferably understood herein, acid fuchsin of the general formula (II) is a compound according to formula:
As preferably understood herein, crystal violet of the general formula (II) is a compound according to formula:
As preferably understood herein, malachite green of the general formula (II) is a compound according to formula:
Where an overall positive charge possessed by the compounds of general formula (I), particularly methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof, the positive charge is balanced by a necessary counterion or counterions. The counterion(s) may be the counterion(s) indicated hereinabove and represented by the abbreviation LG, however the counterion(s) of the present invention is not particularly limited and may include counterions well described in the art.
In a preferred embodiment of the present invention, the target nucleic acid is amplified by a loop- mediated isothermal amplification (LAMP) method.
Within the method of the present invention, It is preferred that amplification is carried out at a constant temperature, in particular using a LAMP method. In some embodiments of the invention, the LAMP method uses 6 primer oligonucleotides comprising a forward outer primer (F3), backward outer primer (B3), forward inner primer (FIP), backward inner primer (BIP), loop primer forward (LF) and loop primer backward (LB) and a polymerase with strand displacement activity to identify a target region on the target nucleic acid. These terms are commonly used in methods related to LAMP, such as those described by Nagamine et al. 2002. Molecular and Cellular Probes 16. 223-229. The F3 and B3 primers are strand invasion oligonucleotides used for the elongation step. The addition of loop primers significantly accelerates amplification, increasing sensitivity and reducing reaction time.
The inventors of the present invention found that amplification of the target nucleic acid by a LAMP method is advantageous since it does not require thermal cycling which necessitates large and complicated equipment to produce detectable amounts of amplified nucleic acid. It is well understood in the art that the LAMP method is a highly sensitive and specific diagnostic method. The use of the LAMP method therefore is well suited for point-of-care and at-home self-tests, which require that the method is fast, efficient and useable by non-medical professionals.
In some embodiments of the present invention, the target nucleic acid is DNA or RNA.
In some embodiments of the present invention, the amplified nucleic acid is single or double stranded nucleic acid.
In some embodiments of the present invention, the test strip comprises a control line downstream of the immobilized leuco dye and/or immobilized nucleophile.
The term “control line”, as used herein, refers to a region of the test strip, generally downstream of the test line(s), which is used to indicate that the sample has flowed through the test line(s). Generally, the control line comprises one or more immobilized reagents capable of providing an indication that the sample has passed through the test lines. The skilled person is aware of typical reagents comprised in
the control line of test strips. In preferred embodiments of the invention, the control line provides a visible signal upon contact with the sample. The present invention may comprise at least one, and optionally more control lines, but does not necessarily do so.
In one embodiment of the invention, the control line comprises an immobilized 3, 3’, 5,5’- tetramethylbenzidine.
Immobilized 3,3’,5,5’-tetramethylbenzidine (TMB) is a typical reagent used for control lines on test strips. TMB is oxidised by the enzyme horseradish peroxidase, which produces a visible color change from colorless to blue. In preferred embodiments of the invention, the primers used for the amplification of the target nucleic acid would comprise horseradish peroxidase, thereby producing amplified nucleic acids containing horseradish peroxidase. Post-amplified samples containing horseradish peroxidase which flow to the control line react with TMB and provide a visible signal that the sample has flowed through the test strip and test lines(s).
In some embodiments of the invention, TMB is immobilized on a cellulose acetate, mixed cellulose ester or chitosan polymer. The immobilization may be, but is not limited to, chemical immobilization via covalent bond formation, or physical immobilization via adsorption or absorption.
In a preferred embodiment of the invention, the control line comprises a leuco dye immobilized on bentonite clay.
The term “bentonite clay”, as used herein, refers to an absorbent swelling clay comprising mainly of montmorillonite - a soft phyllosilicate group of minerals.
The inventors of the present invention surprisingly found that a solid mixture comprising the bentonite clay and leuco dye immobilized on a test strip may act as reagents capable of providing a visible signal on the control line. The inventors found that a control line comprising a mixture of bentonite clay and leuco dye provides a visible signal upon contact with a sample solution indicating that a leaving group on the leuco dye dissociates upon interaction with the solution. A color change is observed irrespective of whether the sample contains the amplified nucleic acid.
In one embodiment of the invention, the target nucleic acid is bacterial or protozoal DNA.
In preferred embodiments of the invention, the bacterial or protozoal DNA is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis.
The method of the present invention is particularly suitable for the detection of target nucleic acids derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. The method of the present invention therefore provides a simple and efficient means for detecting a signal from the nucleic acid originating from a sexually transmitted pathogenic organism and indicating to the user whether or not they have been infected.
In one embodiment of the invention, the invention provides a device or kit for detecting a target nucleic acid, wherein the device comprises: a) a compartment for the amplification of a target nucleic acid to give an amplified nucleic acid, b) a leuco dye immobilized on a test strip, c) a flow path for the amplified nucleic acid to be in contact with the immobilized leuco dye.
The term “compartment for amplification”, as used herein, refers to any structure or container which may be used for the amplification of the target nucleic acid. The material of the container is not particularly limited but may for example be comprised of a plastic material. In preferred embodiments of the invention, the amplification compartment is in fluidic communication with the test strip, to enable the detection of the amplified nucleic acid.
Advantageously, the device of the present invention will be suitable for providing a "one-step" detection of nucleic acids derived from pathogens causing STIs. In particular, after the amplification of the target nucleic acid, the amplified sample may be flowed through the test strip to provide a visual signal which directly indicates the presence or absence of a pathogen derived nucleic acid, without performing any additional steps.
In some embodiments of the invention, the device or kit of the invention contains a leuco dye which is immobilized on a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
In some embodiments of the device or kit contains a test strip comprising the polycarboxylate polymer or agarose in the form of a nanobead.
In some embodiments of the device or kit, the leuco dye is immobilized in a reservoir comprising a liquid medium.
In some embodiments of the device or kit, the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10 ) (COR11 ), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group.
In some embodiments of the device or kit a signal is generated where the leuco dye is immobilized by contact between the leuco dye and amplified nucleic acid.
In some embodiments of the device or kit the leuco dye is of the general formula (II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group.
I n some embodiments, the device or kit comprises at least two compartments for the amplification of a target nucleic acid, at least two test strips comprising immobilized leuco dye and at least two flow paths to contact the amplified nucleic acid with the immobilized leuco dye.
Within the present invention, the target nucleic acid may be comprised in a sample obtained from a human subject (e.g. tissue sample, bronchoalveolar lavage, bronchial wash, pharyngeal exudate, tracheal aspirate, blood, serum, plasma, bone, skin, soft tissue, intestinal tract specimen, genital tract specimen, breast milk, lymph, cerebrospinal fluid, pleural fluid, sputum, urine, a nasal secretion, tears, bile, ascites fluid, pus, synovial fluid, vitreous fluid, vaginal secretion, semen and/or urethral tissue). In preferred embodiments of the invention, the sample comprising the target nucleic acid is obtained from urine, urethral swab, endocervical swab or vaginal swab.
Figure 1 Shows the basic concept of the device of the present invention comprising a LAMP compartment (or well) and a lateral flow test strip with a test zone and control zone. The test zone herein would comprise an immobilized leuco dye of general formula (I), wherein a leaving group of the leuco dye dissociates upon interaction with the amplified nucleic acid. The interaction of the leuco dye and nucleic acid would produce a visible light signal.
Figure 2 Shows the basic concept of the device of the present invention comprising a LAMP compartment (or well) and a lateral flow test strip with two test zones and control zone. The first test zone comprises the leuco dye of general formula (II) which forms a complex
with the amplified nucleic acid, the solution of which then flows downstream to a second test zone comprising an immobilized nucleophile. A visible light signal where the nucleophile is immobilized indicates the presence or absence of the amplified nucleic acid.
Figure 3 Shows the immobilization of basic fuchsin on a chitosan polymer.
Examples
General procedure for the non-chemical immobilization ofleuco-dye on polymeric material
A strip of polymeric material was dipped into a solution of leuco-dye and was allowed to incubate for 15- 30 min at room temperature. Subsequently, the polymeric membrane was removed and allowed to dry for another 30 min. Note that the polymeric material may gain the colour of the leuco-dye.
Example of immobilization of methyl green - sodium sulfite leuco-dye of general formula (I) on cellulose acetate
A strip of cellulose acetate membrane was dipped into a solution of leuco-dye and was allowed to incubate for 15-30 min at room temperature. Subsequently, the cellulose acetate membrane was removed and allowed to dry for another 30 min. Note that here methyl green-sodium sulfite leuco-dye (of general formula (I)) is colourless therefore, the cellulose acetate retained its initial colour.
Example of immobilization of methyl green-sodium sulfite leuco-dye of general formula (I) immobilized on polycarboxylate nanobeads
Polycarboxylate nanobeads were added to a solution of methyl green-sodium sulfite based leuco-dye. The mixture was allowed to incubate for 15-30 min at room temperature. Subsequently, the polycarboxylate nanobeads were allowed to dry for another 30 min. Note that here methyl green-sodium sulfite leuco-dye (of general formula (I)) is colourless therefore, the polycarboxylate nanobeads retain their initial colour.
General procedure for the chemical immobilization ofleuco-dyes on polymeric material
A Functionalized polymeric material is conjugated to a functionalized dye through a chemical reaction. Subsequently, the obtained polymeric material is reacted to a nucleophile (e.g., sodium sulfite) resulting in a chemically immobilized leuco-dye. The product can be purified in several ways including washing accompanied by centrifugation.
Example with basic fuchsin-sodium sulfite leuco-dye of general formula (I) immobilized on chitosan polymers
Chitosan (1.2 g) was dissolved in 60 mL (2% acetic acid) solution in a 150 mL Erlenmeyer flask equipped with a Teflon-coated magnetic stir bar. The solution was stirred for 30 min at RT followed by addition of
basic fuchsin (470 l_, 5.1 x 10-3 mmol) to the light yellow viscous chitosan solution whilst stirring for 30 min further. Acetaldehyde (285 L, 5.1 x 1 O~3 mmol) was added to the mixture, and a white low-viscous solution was formed. The reaction mixture was stirred at 70 °C for 18 h. A 3 M NaOH solution was added gradually to the reaction mixture with vigorous stirring and a pH of up to 7 was attained, where a pink precipitate was formed. The precipitate was separated from the supernatant using a centrifuge for 10 min and washed several times with water and ethanol 70%, dried in a vacuum oven at 50 °C for 6 h and stored in a glass vial. IR: v (cm 1) = 3100, 1650, 1480, 1470, 1100, 1050, 920, 800.
General detection of nucleic acids with immobilized leuco-dye
A strip of polymeric material with the immobilized leuco-dye of general formula (I) (strip 1) was brought into contact with solution containing the target nucleic acids. Another strip of polymeric material with immobilized leuco-dye of general formula (I) (strip R) was dipped into a solution without the target nucleic acids as a control. Strip 1 changed its colour indicating the presence of the target nucleic acids in the solution while strip R retained its initial colour.
Example of chemical immobilization of methyl green - sodium sulfite leuco-dye of general formula (I) on cellulose acetate
A white coloured cellulose acetate strip with the immobilized methyl green-sodium sulfite leuco-dye of general formula (I) (strip 1) was brought into contact with a solution containing target nucleic acids. Another white coloured cellulose acetate strip with immobilized methyl green leuco-dye of general formula (I) (strip R) was brought into contact with a solution without the target nucleic acids as a control. Strip 1 changed its colour to blue indicating the presence of target nucleic acids in the solution while strip R remained white coloured.
Example of chemical immobilization of methyl green - sodium sulfite leuco-dye of general formula (I) on polycarboxylate nanobeads and cellulose acetate
To a solution of 2.5% polycarboxylate nanobeads (3 drops) was added the leuco dye (100 uL) and the mixture was allowed to incubate for 1 h. The solution retained its white color while in solution, indicating that the leuco dye had remained intact. After the incubation, the leuco-dye & nanobead mixture was spread on a cellulose acetate membrane and allowed to dry at room temperature for 1 h. Caution should be taken to not allow the nanobeads to dry prior to spreading it onto a cellulose acetate membrane. If the nanobeads are left to dry without spreading on a cellulose acetate membrane (i.e., the cellulose acetate seems important to keep the color intac)t. Subsequently, the nanobead & cellulose acetate membrane is attached to a lateral flow setup and tested for DNA detection.
Claims
Claims A method for detecting a target nucleic acid, the method comprising the steps of: a) amplifying a target nucleic acid providing an amplified nucleic acid; b) bringing the amplified nucleic acid in contact with an immobilized leuco dye; and c) detecting the presence of the amplified nucleic acid under visible light, wherein the detection of the presence of the amplified nucleic acid is indicative of the presence of the target nucleic acid. The method according to claim 1 , wherein the leuco dye is immobilized on a test strip. The method according to claim 1 or 2, wherein the leuco dye is immobilized onto a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer. The method according to claim 3, wherein the test strip comprises the polycarboxylate polymer or agarose polymer in the form of a nanobead. The method according to claim 1 or 2, wherein the leuco dye is immobilized in a reservoir comprising a liquid medium. The method according to any one of claims 1 to 5, wherein the amplified nucleic acid is detected upon contact with the leuco dye, such that a leaving group (LG) of the leuco dye dissociates and a colour change can be detected under visible light, wherein the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group,
carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10 ) (COR11 ), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group. The method according to claim 6, wherein the amplified nucleic acid is determined to be present if a visible light signal is detected where the leuco dye is immobilized. The method according to claim 6 or 7, wherein the leuco dye of the general formula (I) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof. The method according to any one of claims 1 to 5, wherein the amplified nucleic acid and leuco dye form a complex which is brought into contact with a nucleophile that is immobilized downstream of the leuco dye, wherein the leuco dye of the complex is of the general formula (II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group, and/or wherein the immobilized nucleophile comprises sulfite ions, hydrogen sulfite ions, nitrate ions, nitrite ions, cyanide ions, halide ions, nitrogen nucleophiles, sulfur nucleophiles, alkali metal alkoxides, alkali metal hydroxides or hydride nucleophiles.
The method according to claim 9, wherein the amplified nucleic acid is determined to be present if a visible light signal is detected where the nucleophile is immobilized. The method according to claim 9 or 10, wherein the leuco dye of the general formula (II) is one or more dyes selected from methyl green, basic fuchsin, acid fuchsin, crystal violet, malachite green or derivatives thereof. The method according to any one of claims 1 to 11 , wherein the target nucleic acid is amplified by a loop-mediated isothermal amplification (LAMP) method. The method according to any one of claims 1 to 12, wherein the target nucleic acid is DNA or RNA. The method according to any one of claims 1 to 13, wherein the amplified nucleic acid is single or double stranded nucleic acid. The method according to any one of claims 2 to 14, wherein the test strip comprises a control line downstream of the immobilized leuco dye and/or immobilized nucleophile. The method according to claim 15, wherein the control line comprises an immobilized 3, 3’, 5,5’- tetramethylbenzidine. The method according to claim 15, wherein the control line comprises a leuco dye immobilized on bentonite clay. The method according to any one of claims 1 to 17, wherein the target nucleic acid is bacterial or protozoal DNA. The method according to claim 18, wherein the bacterial or protozoal DNA is derived from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. A device or kit for detecting a target nucleic acid, wherein the device comprises: a) a compartment for the amplification of a target nucleic acid to give an amplified nucleic acid; b) a leuco dye immobilized on a test strip; and c) a flow path for the amplified nucleic acid to be in contact with the immobilized leuco dye. The device or kit according to claim 20, wherein the leuco dye is immobilized on a test strip comprising at least one polymer, wherein the at least one polymer is preferably selected from a cellulose acetate, mixed cellulose ester, polycarboxylate, agarose or chitosan polymer.
The device or kit according to claim 20 or 21 , wherein the test strip comprises the polycarboxylate polymer or agarose in the form of a nanobead. The device or kit according to claim 20, wherein the leuco dye is immobilized in a reservoir comprising a liquid medium. The device or kit according to any one of claims 20 to 23, wherein the leuco dye is of the general formula (I):
wherein R1 and R2 are each independently selected from a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, carboxyl group, hydroxy group, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group; LG represents -SO3R8, -NO3, -NO2, -CN, halogen, -NHR9, -N(COR10 ) (COR11 ), -SR12, -SSR13, -OR14, -NHSNH2, -OH or -H, with R8 representing an alkali metal or a hydrogen atom, R9, R10, R11, R12, R13, R14 independently represent an alkyl group, aryl group, acyl group, alkenyl group or alkynyl group. The device or kit according to claim 24, wherein a signal is generated where the leuco dye is immobilized by contact between the leuco dye and amplified nucleic acid. The device or kit according to claim 20 to 23, wherein the leuco dye is of the general formula (II):
wherein R1 and R2 each independently represent a substituted or unsubstituted aryl group; R3, R4, R5, R6, R7 independently represent a hydrogen, halogen, amino group, alkylamino group, ammonium ion, alkylammonium ion, carboxyl group, hydroxy group, oxocarbenium ion, sulfo group, nitro group, nitrile group, isonitrile group, amido group, alkyl group, aryl group, alkenyl group, alkynyl group, alkoxy group, aryloxy group, alkylthio group, arylthio group, arylamino group, acyl group, alkoxycarbonyl group, aryloxycarbonyl group, alkylsulfonyl group or arylsulfonyl group. The device or kit according to any one of claims 20 to 26, wherein the device or kit comprises at least two compartments for the amplification of a target nucleic acid, at least two test strips comprising immobilized leuco dye and at least two flow paths to contact the amplified nucleic acid with the immobilized leuco dye. A method of diagnosing, and/or prognosing a disease by detecting the presence of a target nucleic acid using the method of any one of claims 1 to 19. The method of claim 28, wherein the disease is an infectious disease. The method of claim 29, wherein the infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. A method of treating an infectious disease, wherein the method comprises administering to a subject identified as having or developing an infectious disease using the method of any one of claims 1 to 19 or the device or kit of any one of claims 20 to 27 an appropriate treatment for said disease. The method of claim 31 , wherein the infectious disease comprises one or more selected from Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium or Trichomonas vaginalis. 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22184563.9 | 2022-07-12 | ||
EP22184563 | 2022-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024013271A1 true WO2024013271A1 (en) | 2024-01-18 |
Family
ID=82558092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/069406 WO2024013271A1 (en) | 2022-07-12 | 2023-07-12 | Colorimetric nucleic acid detection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024013271A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2620508A1 (en) * | 2010-09-22 | 2013-07-31 | Kaneka Corporation | Method and device for detecting nucleic acid, and kit |
EP2682480A1 (en) * | 2011-03-04 | 2014-01-08 | Kaneka Corporation | Nucleic acid detection method, and device and kit for use in same |
US9127308B2 (en) | 2002-03-07 | 2015-09-08 | Atlas Genetics Limited | Nucleic acid probes, their synthesis and use |
WO2017117666A1 (en) * | 2016-01-08 | 2017-07-13 | Advanced Theranostics Inc. | Fully integrated, stand-alone, point-of-care device to detect target nucleic acids |
-
2023
- 2023-07-12 WO PCT/EP2023/069406 patent/WO2024013271A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9127308B2 (en) | 2002-03-07 | 2015-09-08 | Atlas Genetics Limited | Nucleic acid probes, their synthesis and use |
EP2620508A1 (en) * | 2010-09-22 | 2013-07-31 | Kaneka Corporation | Method and device for detecting nucleic acid, and kit |
EP2682480A1 (en) * | 2011-03-04 | 2014-01-08 | Kaneka Corporation | Nucleic acid detection method, and device and kit for use in same |
WO2017117666A1 (en) * | 2016-01-08 | 2017-07-13 | Advanced Theranostics Inc. | Fully integrated, stand-alone, point-of-care device to detect target nucleic acids |
Non-Patent Citations (4)
Title |
---|
ALLGöWER STEFANIE M. ET AL: "The Development of Highly Specific and Sensitive Primers for the Detection of Potentially Allergenic Soybean (Glycine max) Using Loop-Mediated Isothermal Amplification Combined with Lateral Flow Dipstick (LAMP-LFD)", FOODS, vol. 9, no. 4, 1 January 2020 (2020-01-01), CH, pages 423, XP055772741, ISSN: 2304-8158, DOI: 10.3390/foods9040423 * |
MIYAMOTO SHIGEHIKO ET AL: "Method for colorimetric detection of double-stranded nucleic acid using leuco triphenylmethane dyes", ANALYTICAL BIOCHEMISTRY, vol. 473, 1 March 2015 (2015-03-01), Amsterdam, NL, pages 28 - 33, XP093086155, ISSN: 0003-2697, DOI: 10.1016/j.ab.2014.12.016 * |
NAGAMINE ET AL., MOLECULAR AND CELLULAR PROBES, vol. 16, 2002, pages 223 - 229 |
TRINH KIEU THE LOAN ET AL: "Fully integrated and slidable paper-embedded plastic microdevice for point-of-care testing of multiple foodborne pathogens", BIOSENSORS AND BIOELECTRONICS, vol. 135, 11 April 2019 (2019-04-11), pages 120 - 128, XP085681454, ISSN: 0956-5663, DOI: 10.1016/J.BIOS.2019.04.011 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102310223B1 (en) | Composition for Cell-lysis to apply to a structure with a lab-on-paper chip | |
Sivakumar et al. | Ultraviolet-induced in situ gold nanoparticles for point-of-care testing of infectious diseases in loop-mediated isothermal amplification | |
KR101890472B1 (en) | Primers and the Composition for isothermal amplification reaction to detect the pathogens and Method for Rapid and Visual Diagnosis in sexually transmitted infections using thereof | |
CN110791592A (en) | Primer and kit for rapidly detecting African swine fever virus | |
Ruang-Areerate et al. | Distance-based paper device using combined SYBR safe and gold nanoparticle probe LAMP assay to detect Leishmania among patients with HIV | |
Chen et al. | Visual and rapid identification of Chlamydia trachomatis and Neisseria gonorrhoeae using multiplex loop-mediated isothermal amplification and a gold nanoparticle-based lateral flow biosensor | |
CA3073954A1 (en) | Nicking and extension amplification reaction (near) of respiratory syncytial virus species | |
WO2024013271A1 (en) | Colorimetric nucleic acid detection | |
CN112852928A (en) | Multiplex nucleic acid amplification product detection method and kit | |
CN103740836B (en) | Fluorescent quantitative PCR (Polymerase Chain Reaction) primers for detecting mycoplasma pneumoniae (MP) and application thereof | |
KR102551477B1 (en) | Kit for detecting target materials and method for detecting target materials using the same | |
CN110592186B (en) | AND molecular logic gate sensing system AND preparation method AND application thereof | |
JPH06502305A (en) | Methods and pharmaceutical kits useful for detecting microorganisms associated with cavity infections | |
CN215250842U (en) | Nucleic acid detection device that can seal | |
Chen et al. | A nanoparticle-based biosensor combined with multiple cross displacement amplification for the rapid and visual diagnosis of Neisseria gonorrhoeae in clinical application | |
KR102393392B1 (en) | A composition for syphilis diagnosis and a multi-isothermal amplification primer set, and a kit with improved speed, accuracy and portability using the same and a visual diagnosis method using the diagnostic kit | |
CN105463133A (en) | Swine fever virus DNA/RNA (deoxyribonucleic acid/ribonucleic acid) heterozygosis probe-process detection kit and detection method thereof | |
KR102392567B1 (en) | A composition for chlamydia diagnosis and a multi-isothermal amplification primer set, and a kit with improved speed, accuracy and portability using the same and a visual diagnosis method using the diagnostic kit | |
KR102392573B1 (en) | A primer set for diagnosing multiple sexually transmitted diseases including chlamydia and gonorrhea, a simultaneous multi-molecular diagnosis method using the same, and a lab-on-paper-based diagnostic kit | |
Mao et al. | A microfluidic-chip-based system with loop-mediated isothermal amplification for rapid and parallel detection of Trichomonas vaginalis and human papillomavirus | |
US8741568B2 (en) | Detection of human papillomavirus | |
JP6181660B2 (en) | Detection of Streptococcus pneumoniae in blood | |
KR20230081570A (en) | Household lab-on-paper diagnostic chip comprising a composition for diagnosing gonorrhea | |
Shen et al. | Evaluation of the real-time fluorescence loop-mediated isothermal amplification assay for the detection of Ureaplasma urealyticum | |
KR102468964B1 (en) | A primer set for diagnosing multiple mosquito-borne infectious diseases including dengue, zika and chikungunya, a simultaneous multi-molecular diagnosis method using the same, and a lab-on-paper-based diagnostic kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23741401 Country of ref document: EP Kind code of ref document: A1 |